Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antidepressant effect of ketamine
IRCT20090801002266N8Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine in major depressive disorder (MDD), sponsored by Isfahan University of Medical Sciences. Started Oct 2018; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on IRCT20090801002266N8.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090801002266N8.